211 related articles for article (PubMed ID: 18567871)
1. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?
Soltys J; Gong B; Kaminski HJ; Zhou Y; Kusner LL
Ann N Y Acad Sci; 2008; 1132():220-4. PubMed ID: 18567871
[TBL] [Abstract][Full Text] [Related]
2. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
[TBL] [Abstract][Full Text] [Related]
3. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
[TBL] [Abstract][Full Text] [Related]
4. RNA expression analysis of passive transfer myasthenia supports extraocular muscle as a unique immunological environment.
Zhou Y; Kaminski HJ; Gong B; Cheng G; Feuerman JM; Kusner L
Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4348-59. PubMed ID: 24917137
[TBL] [Abstract][Full Text] [Related]
5. Differences between ocular and generalized myasthenia gravis: binding characteristics of anti-acetylcholine receptor antibody against bovine muscles.
Hayashi M; Kida K; Yamada I; Matsuda H; Tsuneishi M; Tamura O
J Neuroimmunol; 1989 Feb; 21(2-3):227-33. PubMed ID: 2913046
[TBL] [Abstract][Full Text] [Related]
6. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
7. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
8. Extraocular muscle characteristics related to myasthenia gravis susceptibility.
Liu R; Xu H; Wang G; Li J; Gou L; Zhang L; Miao J; Li Z
PLoS One; 2013; 8(2):e55611. PubMed ID: 23409007
[TBL] [Abstract][Full Text] [Related]
9. Are linear AChR epitopes the real culprit in ocular myasthenia gravis?
Wu X; Tüzün E
Med Hypotheses; 2017 Feb; 99():26-28. PubMed ID: 28110692
[TBL] [Abstract][Full Text] [Related]
10. Differences in acetylcholine receptor-antibody interactions between extraocular and extremity muscle fibers.
Oda K
Ann N Y Acad Sci; 1993 Jun; 681():238-55. PubMed ID: 8357165
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of ocular tissues to autoimmune diseases.
Kaminski HJ; Li Z; Richmonds C; Ruff RL; Kusner L
Ann N Y Acad Sci; 2003 Sep; 998():362-74. PubMed ID: 14592898
[TBL] [Abstract][Full Text] [Related]
12. Complement associated pathogenic mechanisms in myasthenia gravis.
Tüzün E; Christadoss P
Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
[TBL] [Abstract][Full Text] [Related]
13. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis.
MacLennan C; Beeson D; Buijs AM; Vincent A; Newsom-Davis J
Ann Neurol; 1997 Apr; 41(4):423-31. PubMed ID: 9124798
[TBL] [Abstract][Full Text] [Related]
14. Antigenic difference of acetylcholine receptor between single and multiple form endplates of human extraocular muscle.
Oda K; Shibasaki H
Brain Res; 1988 May; 449(1-2):337-40. PubMed ID: 2456129
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
16. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
[TBL] [Abstract][Full Text] [Related]
17. Age-related resistance to experimental autoimmune myasthenia gravis in rats.
Graus YM; Verschuuren JJ; Spaans F; Jennekens F; van Breda Vriesman PJ; De Baets MH
J Immunol; 1993 May; 150(9):4093-103. PubMed ID: 8386206
[TBL] [Abstract][Full Text] [Related]
18. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
19. Complement and cytokine based therapeutic strategies in myasthenia gravis.
Tüzün E; Huda R; Christadoss P
J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of myasthenia gravis.
Hughes BW; Moro De Casillas ML; Kaminski HJ
Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
